Study summary

Ponatinib doubled the rate of deep remissions compared with imatinib

PhALLCON trial · 245 people, phase 3 · Published June 2024, JAMA; FDA approved March 2024

34.4%deep (MRD-negative) remission, vs 16.7% with imatinib

What was tested

Ponatinib, a third-generation BCR::ABL1 inhibitor, against imatinib, each with reduced-intensity chemotherapy, for newly diagnosed Ph+ ALL in adults.

What they found

MRD-negative complete remission was 34.4% vs 16.7%.
Artery blockages, a known ponatinib risk, were uncommon (2.5% vs 1.2%).

What it means

Made ponatinib the preferred pill partner for Ph+ ALL.

JAMA, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.